Repare Therapeutics Inc. (RPTX) Financial Statements (2023 and earlier)
Company Profile
| Business Address |
7171 FREDERICK BANTING SAINT-LAURENT, QC H4S 1Z9 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 6/30/2023 MRQ | 12/31/2022 | 12/31/2021 | 12/31/2020 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 343,941,000 | 341,866,000 | 333,710,000 | |||
| Cash and cash equivalents | 159,521,000 | 334,427,000 | 326,184,000 | |||
| Short-term investments | 184,420,000 | 7,439,000 | 7,526,000 | |||
| Receivables | 1,525,000 | |||||
| Prepaid expense | 5,715,000 | 6,314,000 | 6,678,000 | |||
| Other undisclosed current assets | 2,798,000 | 3,234,000 | 6,164,000 | |||
| Total current assets: | 353,979,000 | 351,414,000 | 346,552,000 | |||
| Noncurrent Assets | ||||||
| Operating lease, right-of-use asset | 5,371,000 | 7,491,000 | 4,674,000 | |||
| Property, plant and equipment | 4,228,000 | 5,604,000 | 3,948,000 | |||
| Restricted cash and investments | 212,000 | |||||
| Deferred income tax assets | 3,620,000 | 1,412,000 | ||||
| Other noncurrent assets | 497,000 | 586,000 | 288,000 | |||
| Total noncurrent assets: | 10,096,000 | 17,301,000 | 10,534,000 | |||
| TOTAL ASSETS: | 364,075,000 | 368,715,000 | 357,086,000 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities | 7,997,000 | 8,079,000 | 5,476,000 | |||
| Taxes payable | ✕ | ✕ | 523,000 | 18,000 | ||
| Employee-related liabilities | ✕ | ✕ | 4,867,000 | 2,771,000 | ||
| Accounts payable | 461,000 | 2,302,000 | 2,251,000 | |||
| Accrued liabilities | 7,536,000 | 387,000 | 436,000 | |||
| Deferred revenue | 53,102,000 | 11,921,000 | 2,073,000 | |||
| Other liabilities | 271,000 | 377,000 | 184,000 | |||
| Other undisclosed current liabilities | 17,249,000 | 14,712,000 | 3,281,000 | |||
| Total current liabilities: | 78,619,000 | 35,089,000 | 11,014,000 | |||
| Noncurrent Liabilities | ||||||
| Long-term debt and lease obligation: | 5,592,000 | 3,308,000 | ||||
| Liabilities, other than long-term debt | 5,939,000 | 39,613,000 | 55,934,000 | |||
| Deferred revenue | 2,682,000 | 39,613,000 | 55,934,000 | |||
| Operating lease, liability | 3,257,000 | 5,592,000 | 3,308,000 | |||
| Total noncurrent liabilities: | 5,939,000 | 45,205,000 | 59,242,000 | |||
| Total liabilities: | 84,558,000 | 80,294,000 | 70,256,000 | |||
| Equity | ||||||
| Equity, attributable to parent | 279,517,000 | 288,421,000 | 286,830,000 | |||
| Common stock | 482,032,000 | 480,699,000 | 384,313,000 | |||
| Additional paid in capital | 37,226,000 | 17,988,000 | 5,875,000 | |||
| Accumulated other comprehensive loss | (428,000) | |||||
| Accumulated deficit | (239,313,000) | (210,266,000) | (103,358,000) | |||
| Total equity: | 279,517,000 | 288,421,000 | 286,830,000 | |||
| TOTAL LIABILITIES AND EQUITY: | 364,075,000 | 368,715,000 | 357,086,000 | |||
Income Statement (P&L) (USD)
| 6/30/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|---|
| Gross profit: | (1,873,000) | (890,000) | |||
| Operating expenses | (151,626,000) | (116,260,000) | (54,437,000) | ||
| Other undisclosed operating income | 131,830,000 | 9,473,000 | 1,025,000 | ||
| Operating income (loss): | (19,796,000) | (108,660,000) | (54,302,000) | ||
| Nonoperating income (expense) | 5,896,000 | 74,000 | (440,000) | ||
| Investment income, nonoperating | 5,631,000 | 259,000 | 240,000 | ||
| Gain (loss), foreign currency transaction, before tax | 308,000 | (144,000) | (664,000) | ||
| Other nonoperating expense | (43,000) | (41,000) | (16,000) | ||
| Income (loss) from continuing operations before income taxes: | (13,900,000) | (108,586,000) | (54,742,000) | ||
| Income tax expense (benefit) | (15,147,000) | 1,678,000 | 1,325,000 | ||
| Loss from continuing operations: | (29,047,000) | (106,908,000) | (53,417,000) | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | (106,908,000) | (53,417,000) | ||
| Net loss available to common stockholders, diluted: | (29,047,000) | (106,908,000) | (53,417,000) | ||
Comprehensive Income (USD)
| 6/30/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|---|
| Net loss: | (29,047,000) | (106,908,000) | (53,417,000) | ||
| Other comprehensive loss | (428,000) | ||||
| Other undisclosed comprehensive loss | |||||
| Comprehensive loss: | (29,475,000) | (106,908,000) | (53,417,000) | ||
| Other undisclosed comprehensive income, net of tax, attributable to parent | |||||
| Comprehensive loss, net of tax, attributable to parent: | (29,475,000) | (106,908,000) | (53,417,000) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.